Literature DB >> 26051810

Clinical course and long-term outcome following venoarterial extracorporeal life support-facilitated interhospital transfer of patients with circulatory failure.

Simon Schopka1, Alois Philipp2, Michael Hilker2, Thomas Müller3, Markus Zimmermann4, Matthias Arlt5, Leopold Rupprecht2, Christof Schmid2, Dirk Lunz6.   

Abstract

BACKGROUND: Interhospital transfer of patients experiencing circulatory failure and shock has a significant risk of cardiovascular deterioration and death. Extracorporeal life support (ECLS) is a rescue tool for hemodynamic stabilization that makes patient transportation much safer.
METHODS: Demographic data, clinical course, and outcome data were reviewed for patients who underwent placement of a venoarterial ECLS in a remote hospital and were transported to our tertiary care facility.
RESULTS: 68 patients were transported to our center with ECLS. The majority of these patients (79%) underwent cardiopulmonary resuscitation during or immediately prior to ECLS initiation. The mean patient age was 52 years, and 53 patients were male. The most common underlying diagnosis was acute coronary syndrome (60%). Overall, 23 patients underwent consecutive cardiosurgical procedures, including coronary artery bypass grafting in 12, and left ventricular assist device and biventricular assist device implantation in 11. The median duration of ECLS was 5 days. None of the patients died during transportation. Twelve of the surgically treated patients survived, as well as 21 patients with non-surgical treatment, which resulted in an overall survival of 33 patients (48.5%).
CONCLUSION: ECLS-facilitated patient transfer enables safe interhospital transfer of critically ill patients. In this study, a relevant percentage of patients were in need of a cardiosurgical intervention. The long-term survival rate of these patients supports the further use of this time-, cost- and personnel-demanding strategy.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiopulmonary resuscitation; Extracorporeal circulation; Heart arrest; Shock

Mesh:

Year:  2015        PMID: 26051810     DOI: 10.1016/j.resuscitation.2015.05.021

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  6 in total

1.  Outcomes of venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock: systematic review and meta-analysis.

Authors:  Ashley R Wilson-Smith; Yulia Bogdanova; Stephanie Roydhouse; Kevin Phan; David H Tian; Tristan D Yan; Antonio Loforte
Journal:  Ann Cardiothorac Surg       Date:  2019-01

2.  Acute heart failure due to giant left atrium: remote ECLS implantation for interhospital transfer and bridging to decision.

Authors:  Hazem El Beyrouti; Martin Oberhoffer; Angela Kornberger; Andres Beiras-Fernandez; Christian-Friedrich Vahl
Journal:  Innov Surg Sci       Date:  2018-12-20

3.  Factors associated with hemolysis during extracorporeal membrane oxygenation (ECMO)-Comparison of VA- versus VV ECMO.

Authors:  Hannah Appelt; Alois Philipp; Thomas Mueller; Maik Foltan; Matthias Lubnow; Dirk Lunz; Florian Zeman; Karla Lehle
Journal:  PLoS One       Date:  2020-01-27       Impact factor: 3.240

4.  The 'Weekend Effect' in adult patients who receive extracorporeal cardiopulmonary resuscitation after in- and out-of-hospital cardiac arrest.

Authors:  Dirk Lunz; Daniele Camboni; Alois Philipp; Bernhard Flörchinger; Armando Terrazas; Thomas Müller; Christof Schmid; Claudius Diez
Journal:  Resusc Plus       Date:  2020-11-21

Review 5.  Transportation of Critically Ill Patients on Extracorporeal Membrane Oxygenation.

Authors:  L Mikael Broman; Björn Frenckner
Journal:  Front Pediatr       Date:  2016-06-13       Impact factor: 3.418

6.  Long-term follow-up and quality of life in patients receiving extracorporeal membrane oxygenation for pulmonary embolism and cardiogenic shock.

Authors:  Tobias J Lange; Daniele Camboni; Andrea Stadlbauer; Alois Philipp; Sebastian Blecha; Matthias Lubnow; Dirk Lunz; Jing Li; Armando Terrazas; Christof Schmid
Journal:  Ann Intensive Care       Date:  2021-12-24       Impact factor: 6.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.